Adenosine
5-monophosphate activated protein kinase (AMPK) plays an important role in
regulation of homeostasis. Dysregulation of AMPK can result in many diseases
which includes obesity and type 2 diabetes. Several studies have also suggested
that AMPK are also associated with the development of neurological diseases and
cancer.
Download the sample
report @ https://www.pharmaproff.com/request-sample/1172
Despite of many
advancements in the development of anti-cancer therapies, cancer is still one
of the major causes of deaths, globally. AMPK is one of the newest targets for
the anti-cancer therapies, which modulates cellular protein and lipid
metabolism, affecting the cellular growth and division. The importance of AMPK
mediate signalling in various diseases and its complexity suggested that there
is an urgent need for the development of additional AMPK modulators that can be
used to not only disturb the mechanism of action but also as a drug candidate
for therapeutic development. Also, researches have demonstrated that, in-depth
knowledge and evidences are required to produce desired physiological outcomes
by developing specific targeted therapies with reduced adverse events and
better efficacy.
Get the detailed
analysis @ https://www.pharmaproff.com/report/ampk-modulators-therapeutics
Esperion Therapeutics
Inc. is in the process of developing Bempedoic acid as a small molecule which
acts as an AMPK stimulant for the treatment of hypercholesterolemia,
dyslipidaemia, and hypertension. Betagenon AB, Boehringer Ingelheim
International GmbH, and Poxel SA are some other companies having pipeline AMPK
modulators for the management of several diseases.
0 Comments